BEST OF THE BROKERS

first_imgSunday 7 November 2010 8:19 pm whatsapp KCS-content Share Show Comments ▼ Tags: NULL center_img by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeTotal PastThe Ingenious Reason There Are No Mosquitoes At Disney WorldTotal PastMoneyPailShe Was A Star, Now She Works In ScottsdaleMoneyPailElite HeraldExperts Discover Girl Born From Two Different SpeciesElite HeraldZen HeraldThe Truth About Why ’40s Actor John Wayne Didn’t Serve In WWII Has Come To LightZen Heraldmoneycougar.comThis Proves The Osmonds Weren’t So Innocentmoneycougar.comMisterStoryWoman Files For Divorce After Seeing This Photo – Can You See Why?MisterStoryTaonga: The Island FarmThe Most Relaxing Farm Game of 2021. No InstallTaonga: The Island FarmAlphaCute30 Rules That All “Hells Angels” Have To FollowAlphaCuteAtlantic MirrorA Kilimanjaro Discovery Has Proved This About The BibleAtlantic Mirror BEST OF THE BROKERS Read This NextRicky Schroder Calls Foo Fighters’ Dave Grohl ‘Ignorant Punk’ forThe WrapCNN’s Brian Stelter Draws Criticism for Asking Jen Psaki: ‘What Does theThe WrapDid Donald Trump Wear His Pants Backwards? Kriss Kross Memes Have AlreadyThe WrapHarvey Weinstein to Be Extradited to California to Face Sexual AssaultThe WrapNewsmax Rejected Matt Gaetz When Congressman ‘Reached Out’ for a JobThe WrapPink Floyd’s Roger Waters Denies Zuckerberg’s Request to Use Song in Ad:The Wrap’The View’: Meghan McCain Calls VP Kamala Harris a ‘Moron’ for BorderThe Wrap’Sex and the City’ Sequel Series at HBO Max Adds 4 More ReturningThe Wrap2 HFPA Members Resign Citing a Culture of ‘Corruption and Verbal Abuse’The Wrap whatsapp ROYAL BANK OF SCOTLANDStandard & Poor’s has upgraded the State-backed bank to “buy” from “hold”, but has trimmed its 12 month target price by 1p to 57p. The broker notes that RBS’s results last week confirmed the bank is on track to deliver profit next year, and expects a significant uplift in profitability over the next two years.DECHRABrewin Dolphin rates the veterinary pharmaceutical group a “hold” with a 12 month target price of 500p. The broker has upgraded its revenue forecasts by five per cent this year and nine per cent next year on the back of the firm’s $42m acquisition of DermaPet in October, though it believes sales in the US are likely to miss targets.UNILEVEREvolution Securities rates the utility a “buy” with an upgraded target price of £21. The broker has upgraded its 2010 earnings before interest and tax by 0.15 per cent, resulting in a 1.4 per cent lift in earnings per share to €1.40. It adds that reassuring results for the third quarter could be a catalyst for re-rating the stock. last_img

Leave a comment